Innovations in Immune Profiling for Clinical Research
 

CAP Today: Innovations in Immune Profiling for Clinical Research

In this webinar we heard leading experts discuss how they are leveraging flow cytometry to expand and improve the immune profiles of every precious sample in clinical research trials.

Presenters:

  • Caroline Roe, MLI
  • Sasidhar Vemula, PhD
  • Vinicius Motta, PhD

Register to watch

CAP TODAY

April 25, 2022 | On Demand

View details

PRESENTERS

Cutting Edge Cytometry and Clinical Trials: ​A Case Study


Caroline Roe, MLI
Managing Director
Cancer & Immunology Core
Vanderbilt University

 

Caroline Roe

Roe shares her approach to high-parameter immune monitoring panel design, as well as the planning and execution of clinical correlative studies. She discusses the utility of patient-specific analysis tools for high-dimensional cytometry data and inferring biological significance from research assays.

Register to watch on demand

Method Validation Studies Using the Maxpar® Direct™ Immune Profiling Assay™


Sasidhar Vemula, PhD
Lead Scientist
Translational Biomarker
Labcorp Drug Development
Vanderbilt University
Sasidhar Vemula

Vemula details the validation process for two Maxpar panels offered by Labcorp: the Maxpar Direct Immune Profiling Assay and the Maxpar Basic Human T Cell Immuno-Oncology Panel Set.



Register to watch on demand

Efficient, High-Content Immune Profiling with CyTOF® XT and ​Maxpar Direct Immune Profiling Assay


Vinicius Motta, PhD
Field Applications Specialist
Standard BioTools
Vinicius Motta

Motta describes how fully automated flow cytometry with CyTOF XT combined with the deep immune profiling provided by the Maxpar Direct Immune Profiling Assay standardizes and simplifies a crucial application for clinical research.


Register to watch on demand

Submit the form below to watch the videos.

Unless explicitly and expressly stated otherwise, all Standard BioTools products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices